AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan)
Journal
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Date Issued
2019
Author(s)
Todorovic, Vladimir
Aapro, Matti
Pavlidis, Nicholas
Arsovski, Oliver
Belkacemi, Yazid
Babovic, Nada
Bidard, François Clément
Bourhafour, Mouna
Beslija, Semir
Boussen, Hamouda
Cetnikovic, Bojana
Ceric, Timur
Cicmil, Nada
Crnogorac, Nebojsa
Cuedari, Enkelejda
De Laurentis, Michele
Dragovich, Tomislav
Durutovic, Ivana
Dzamic, Zoran
Dzodic, Radan
Eri, Zivka
Geara, Fady
Khalil, Ahmed
Kerrou, Khaldoun
Knezevic Usaj, Slavica
Kovcin, Vladimir
Koroveshi, Dhurata
Kristo Pema, Anila
Kuten, Abraham
Lakicevic, Jadranka
Lukovac, Nevenka
Markovic, Ivan
Markovic, Milan
Mijalkovic, Nenad
Milasevic, Nikola
Mustachi, Giorgio
Ognjenovic, Dragana
Pantelic, Aleksandra
Popovic, Lazar
Radosavljevic, Davorin
Radosevic, Nina
Radulovic, Sinisa
Ristevski, Milan
Rosic, Ivana
Secen, Nevena
Sorat, Milan
Stamatovic, Liljana
Stefanovski, Petar
Tesanovic, Dusanka
Tomasevic, Zorica
Tomasevic, Zoran
Tsoutsou, Pauletta
Turkan, Sedat
Vasev, Nino
Vasovic, Suzana
Vicko, Ferenc
Vrbanec, Damir
Vukmirovic, Filip
Vrdoljak, Eduard
Zaric, Bojan
Zambrovski, Jean Jacques
Cavalli, Franco
Gligorov, Joseph
Abstract
PURPOSE:
Cancer is a leading cause of mortality worldwide. Its incidence is still increasing, particularly in developing countries. Recent progresses further strengthen the differences between low/middle and high-income countries. This situation calls for joint action to reduce inequities in cancer outcomes among the patients. The Association of Radiotherapy and Oncology of the Mediterranean Area (AROME) and the European School of Oncology (ESO), have initiated joint conferences devoted to access to innovations in oncology in the Mediterranean area. The heterogeneity of the economic, political and cultural situations of the different participating countries, offers the opportunity to develop consensus conference.
METHODS:
Cancer prevention and treatment strategies were discussed according to existing international guidelines. The Scientific committee prepared 111 questions with an objective to prioritize the access to treatments and innovations in low/middle-income Mediterranean countries. The results from the votes of 65 oncology experts, coming from 16 countries and 33 institutions have been analysed and access priorities classified accordingly.
RESULTS:
Ninety six percent of the proposed general recommendations concerning national health care strategies, oncology education, and treatment organization were considered to be high priorities. Regarding access to systemic treatments, 41% of the drugs without validated predictive markers and 53% of those with validated predictive markers were considered to be 1st level priority. Only 4 biological tests were considered to be 1st level priority to access to innovation.
CONCLUSIONS:
AROME-ESO consensus offers to cancer specialists from developing countries a basis for discussion with health authorities and payers on the prioritization of access to innovations in cancer care.
Cancer is a leading cause of mortality worldwide. Its incidence is still increasing, particularly in developing countries. Recent progresses further strengthen the differences between low/middle and high-income countries. This situation calls for joint action to reduce inequities in cancer outcomes among the patients. The Association of Radiotherapy and Oncology of the Mediterranean Area (AROME) and the European School of Oncology (ESO), have initiated joint conferences devoted to access to innovations in oncology in the Mediterranean area. The heterogeneity of the economic, political and cultural situations of the different participating countries, offers the opportunity to develop consensus conference.
METHODS:
Cancer prevention and treatment strategies were discussed according to existing international guidelines. The Scientific committee prepared 111 questions with an objective to prioritize the access to treatments and innovations in low/middle-income Mediterranean countries. The results from the votes of 65 oncology experts, coming from 16 countries and 33 institutions have been analysed and access priorities classified accordingly.
RESULTS:
Ninety six percent of the proposed general recommendations concerning national health care strategies, oncology education, and treatment organization were considered to be high priorities. Regarding access to systemic treatments, 41% of the drugs without validated predictive markers and 53% of those with validated predictive markers were considered to be 1st level priority. Only 4 biological tests were considered to be 1st level priority to access to innovation.
CONCLUSIONS:
AROME-ESO consensus offers to cancer specialists from developing countries a basis for discussion with health authorities and payers on the prioritization of access to innovations in cancer care.
File(s)![Thumbnail Image]()
Loading...
Name
24-5-2180.pdf
Description
Public PDF
Size
1013.1 KB
Format
Adobe PDF
Checksum
(MD5):a90ba9d4fe0f115607d72dd2f4799352